Integrating contact tracing and whole-genome sequencing to track the elimination of dog-mediated rabies: An observational and genomic study.
epidemiology
global health
infectious disease
microbiology
next generation sequencing
one health
surveillance
vaccine-preventable
viruses
zoonotic disease
Journal
eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614
Informations de publication
Date de publication:
25 05 2023
25 05 2023
Historique:
received:
30
11
2022
accepted:
24
05
2023
medline:
29
6
2023
pubmed:
25
5
2023
entrez:
25
5
2023
Statut:
epublish
Résumé
Dog-mediated rabies is endemic across Africa causing thousands of human deaths annually. A One Health approach to rabies is advocated, comprising emergency post-exposure vaccination of bite victims and mass dog vaccination to break the transmission cycle. However, the impacts and cost-effectiveness of these components are difficult to disentangle. We combined contact tracing with whole-genome sequencing to track rabies transmission in the animal reservoir and spillover risk to humans from 2010 to 2020, investigating how the components of a One Health approach reduced the disease burden and eliminated rabies from Pemba Island, Tanzania. With the resulting high-resolution spatiotemporal and genomic data, we inferred transmission chains and estimated case detection. Using a decision tree model, we quantified the public health burden and evaluated the impact and cost-effectiveness of interventions over a 10-year time horizon. We resolved five transmission chains co-circulating on Pemba from 2010 that were all eliminated by May 2014. During this period, rabid dogs, human rabies exposures and deaths all progressively declined following initiation and improved implementation of annual islandwide dog vaccination. We identified two introductions to Pemba in late 2016 that seeded re-emergence after dog vaccination had lapsed. The ensuing outbreak was eliminated in October 2018 through reinstated islandwide dog vaccination. While post-exposure vaccines were projected to be highly cost-effective ($256 per death averted), only dog vaccination interrupts transmission. A combined One Health approach of routine annual dog vaccination together with free post-exposure vaccines for bite victims, rapidly eliminates rabies, is highly cost-effective ($1657 per death averted) and by maintaining rabies freedom prevents over 30 families from suffering traumatic rabid dog bites annually on Pemba island. A One Health approach underpinned by dog vaccination is an efficient, cost-effective, equitable, and feasible approach to rabies elimination, but needs scaling up across connected populations to sustain the benefits of elimination, as seen on Pemba, and for similar progress to be achieved elsewhere. Wellcome [207569/Z/17/Z, 095787/Z/11/Z, 103270/Z/13/Z], the UBS Optimus Foundation, the Department of Health and Human Services of the National Institutes of Health [R01AI141712] and the DELTAS Africa Initiative [Afrique One-ASPIRE/DEL-15-008] comprising a donor consortium of the African Academy of Sciences (AAS), Alliance for Accelerating Excellence in Science in Africa (AESA), the New Partnership for Africa's Development Planning and Coordinating (NEPAD) Agency, Wellcome [107753/A/15/Z], Royal Society of Tropical Medicine and Hygiene Small Grant 2017 [GR000892] and the UK government. The rabies elimination demonstration project from 2010-2015 was supported by the Bill & Melinda Gates Foundation [OPP49679]. Whole-genome sequencing was partially supported from APHA by funding from the UK Department for Environment, Food and Rural Affairs (Defra), Scottish government and Welsh government under projects SEV3500 and SE0421.
Sections du résumé
Background
Dog-mediated rabies is endemic across Africa causing thousands of human deaths annually. A One Health approach to rabies is advocated, comprising emergency post-exposure vaccination of bite victims and mass dog vaccination to break the transmission cycle. However, the impacts and cost-effectiveness of these components are difficult to disentangle.
Methods
We combined contact tracing with whole-genome sequencing to track rabies transmission in the animal reservoir and spillover risk to humans from 2010 to 2020, investigating how the components of a One Health approach reduced the disease burden and eliminated rabies from Pemba Island, Tanzania. With the resulting high-resolution spatiotemporal and genomic data, we inferred transmission chains and estimated case detection. Using a decision tree model, we quantified the public health burden and evaluated the impact and cost-effectiveness of interventions over a 10-year time horizon.
Results
We resolved five transmission chains co-circulating on Pemba from 2010 that were all eliminated by May 2014. During this period, rabid dogs, human rabies exposures and deaths all progressively declined following initiation and improved implementation of annual islandwide dog vaccination. We identified two introductions to Pemba in late 2016 that seeded re-emergence after dog vaccination had lapsed. The ensuing outbreak was eliminated in October 2018 through reinstated islandwide dog vaccination. While post-exposure vaccines were projected to be highly cost-effective ($256 per death averted), only dog vaccination interrupts transmission. A combined One Health approach of routine annual dog vaccination together with free post-exposure vaccines for bite victims, rapidly eliminates rabies, is highly cost-effective ($1657 per death averted) and by maintaining rabies freedom prevents over 30 families from suffering traumatic rabid dog bites annually on Pemba island.
Conclusions
A One Health approach underpinned by dog vaccination is an efficient, cost-effective, equitable, and feasible approach to rabies elimination, but needs scaling up across connected populations to sustain the benefits of elimination, as seen on Pemba, and for similar progress to be achieved elsewhere.
Funding
Wellcome [207569/Z/17/Z, 095787/Z/11/Z, 103270/Z/13/Z], the UBS Optimus Foundation, the Department of Health and Human Services of the National Institutes of Health [R01AI141712] and the DELTAS Africa Initiative [Afrique One-ASPIRE/DEL-15-008] comprising a donor consortium of the African Academy of Sciences (AAS), Alliance for Accelerating Excellence in Science in Africa (AESA), the New Partnership for Africa's Development Planning and Coordinating (NEPAD) Agency, Wellcome [107753/A/15/Z], Royal Society of Tropical Medicine and Hygiene Small Grant 2017 [GR000892] and the UK government. The rabies elimination demonstration project from 2010-2015 was supported by the Bill & Melinda Gates Foundation [OPP49679]. Whole-genome sequencing was partially supported from APHA by funding from the UK Department for Environment, Food and Rural Affairs (Defra), Scottish government and Welsh government under projects SEV3500 and SE0421.
Identifiants
pubmed: 37227428
doi: 10.7554/eLife.85262
pii: 85262
pmc: PMC10299823
doi:
pii:
Substances chimiques
Rabies Vaccines
0
Types de publication
Observational Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Wellcome Trust
ID : 107753/A/15/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 095787/Z/11/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 207569/Z/17/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 103270/Z/13/Z
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : R01 AI141712
Pays : United States
Organisme : EPA
ID : EP-C-15-008
Pays : United States
Organisme : Wellcome Trust
Pays : United Kingdom
Informations de copyright
© 2023, Lushasi, Brunker et al.
Déclaration de conflit d'intérêts
KL, KB, MR, EF, GJ, LB, RB, JC, SC, AC, AF, NG, DH, PJ, RK, TL, DM, MM, MM, EM, GM, AM, EM, CN, KN, HN, KO, KR, MS, LS, RS, KH No competing interests declared
Références
Vaccine. 2012 May 21;30(24):3492-502
pubmed: 22480924
Rev Sci Tech. 2018 Aug;37(2):439-449
pubmed: 30747136
Bioinformatics. 2018 Jul 15;34(14):2490-2492
pubmed: 29506019
Euro Surveill. 2008 Mar 13;13(11):
pubmed: 18768130
PLoS One. 2016 Nov 28;11(11):e0167092
pubmed: 27893866
PLoS Negl Trop Dis. 2015 Apr 16;9(4):e0003709
pubmed: 25881058
Bioinformatics. 2008 Jun 1;24(11):1403-5
pubmed: 18397895
Virus Evol. 2016 Apr 09;2(1):vew007
pubmed: 27774300
J Vis Exp. 2019 Jul 10;(149):
pubmed: 31355796
PLoS Negl Trop Dis. 2017 Mar 17;11(3):e0005460
pubmed: 28306717
PLoS Pathog. 2016 Apr 08;12(4):e1005525
pubmed: 27058957
Lancet Glob Health. 2018 Aug;6(8):e828-e829
pubmed: 29929890
Science. 2022 Apr 29;376(6592):512-516
pubmed: 35482879
PLoS Comput Biol. 2018 Dec 17;14(12):e1006554
pubmed: 30557340
Virus Evol. 2018 Jun 08;4(1):vey016
pubmed: 29942656
Vet Sci. 2018 Sep 07;5(3):
pubmed: 30205470
J Med Assoc Thai. 2004 Nov;87(11):1389-93
pubmed: 15825719
Lancet Infect Dis. 2019 Jan;19(1):102-111
pubmed: 30472178
Vaccine. 2018 Sep 5;36(37):5500-5503
pubmed: 30107991
Front Trop Dis. 2022 Jun 20;3:829132
pubmed: 36945698
Comp Immunol Microbiol Infect Dis. 2013 May;36(3):249-61
pubmed: 23260376
Elife. 2023 May 25;12:
pubmed: 37227428
Bioinformatics. 2019 Feb 1;35(3):526-528
pubmed: 30016406
PLoS Pathog. 2022 May 2;18(5):e1010023
pubmed: 35500026
Trans R Soc Trop Med Hyg. 2022 Mar 2;116(3):197-200
pubmed: 34392375
Emerg Infect Dis. 2010 Dec;16(12):1925-30
pubmed: 21122223
J Appl Ecol. 2021 Nov;58(11):2673-2685
pubmed: 35221371
Curr Protoc Bioinformatics. 2020 Mar;69(1):e96
pubmed: 32162851
Emerg Infect Dis. 2013 Apr;19(4):529-33
pubmed: 23628197
Int J Health Policy Manag. 2021 Nov 01;10(11):697-705
pubmed: 33619938
Lancet Infect Dis. 2015 Mar;15(3):320-6
pubmed: 25619149
PLoS Negl Trop Dis. 2013 Aug 22;7(8):e2372
pubmed: 23991233
Sci Rep. 2021 Jun 14;11(1):12476
pubmed: 34127783
PLoS One. 2019 Jan 10;14(1):e0210018
pubmed: 30629634
Front Vet Sci. 2017 Mar 06;4:21
pubmed: 28321400
Bioinformatics. 2011 Nov 1;27(21):3070-1
pubmed: 21926124
Philos Trans R Soc Lond B Biol Sci. 2013 Jun 24;368(1623):20120143
pubmed: 23798691
Vaccine. 2019 Oct 3;37 Suppl 1:A45-A53
pubmed: 30309746
BMC Infect Dis. 2020 Oct 20;20(1):778
pubmed: 33081712
Wellcome Open Res. 2020 Jan 7;5:3
pubmed: 32090172
Virus Evol. 2015 Sep 10;1(1):vev011
pubmed: 27774283
Mol Biol Evol. 2015 Jan;32(1):268-74
pubmed: 25371430
Front Vet Sci. 2017 Mar 14;4:33
pubmed: 28352630
Nature. 2016 Feb 11;530(7589):228-232
pubmed: 26840485
PLoS Negl Trop Dis. 2021 May 21;15(5):e0009414
pubmed: 34019548
Infect Genet Evol. 2016 Mar;38:22-28
pubmed: 26656835
Vaccine. 2003 May 16;21(17-18):1965-73
pubmed: 12706685
Sci Transl Med. 2017 Dec 20;9(421):
pubmed: 29263230